Houston Eye Associates

1. Glaukos Corporation $298,498 46 payments
2. Ocular Therapeutix, Inc. $168,035 3 payments
3. Bausch Health US, LLC $100,251 4 payments
4. Dompe Farmaceutici S.p.A. $89,114 11 payments
5. RxSight Inc $40,000 8 payments
6. Allergan Inc. $25,356 46 payments
7. EyePoint Pharmaceuticals US, Inc. $21,215 1 payment
8. Bausch & Lomb Americas Inc. $20,527 3 payments
9. Shire North American Group Inc $18,472 7 payments
10. Kala Pharmaceuticals, Inc. $7,650 4 payments

1. A Study to Document the Safety and Effectiveness of A New Cohesive Ovd When Compared to A Control Ovd $120,778 7 payments
2. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $116,558 11 payments
3. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $108,518 2 payments
4. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $97,610 15 payments
5. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $73,332 13 payments
6. A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogrens dry eye disease under treatment with Cyclosporine A (PROTEGO-2 study) $63,595 6 payments
7. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $59,517 1 payment
8. Pmcs-002 $40,000 8 payments
9. A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Oxervate (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogrens dry eye disease (PROTEGO-1 study) $25,519 5 payments
10. A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye $21,215 1 payment

1. Other $2,022 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.